Fairvalue-Calculator Fairvalue-Calculator
EN DE

China Resources Double-Crane Pharmaceutical Co (600062) Fair Value & Analysis

Healthcare · CN · Market cap 17.8B CNY

Price¥16.48
Fair Value¥28.81
Upside+74.8%
Quality88/100
Evidence: Medium Range ¥16.51 – ¥43.61

Fair value as of: Jun 24, 2026

Analysis

China Resources Double-Crane Pharmaceutical Co (600062) currently trades at ¥16.48, while our model-based Fair Value estimate is ¥28.81 — implying the stock looks roughly 74.8% undervalued today. We read business quality at 88/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People's Republic of China. The company offers pharmaceutical products for blood pressure and sugar, injections, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, inflammation, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 and is headquartered in Beijing, the People's Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a subsidiary of Beijing Pharmaceutical Group Co., Ltd.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is China Resources Double-Crane Pharmaceutical Co (600062) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥28.81 versus a price of ¥16.48 — about +75% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 600062?
Our 21-model fair value for China Resources Double-Crane Pharmaceutical Co is ¥28.81 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥16.48.
What is the quality score of 600062?
China Resources Double-Crane Pharmaceutical Co has a Quality Score of 88/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.